Modulation of the gut-liver axis by oxymatrine alleviates metabolic dysfunction-associated steatotic liver disease

doi:10.3748/wjg.v32.i16.116187

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 16

This Article

(22)

(35)

(0)

(23)

(735)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Apr 28, 2026; 32(16): 116187
Published online Apr 28, 2026. doi: 10.3748/wjg.v32.i16.116187

Full Size Figure Download Figure

Figure 5 Oxymatrine alters intestinal microbiota composition in metabolic dysfunction-associated steatotic liver disease rats. A: Linear discriminant analysis effect size analysis results; B: Cladogram of linear discriminant analysis effect size analysis; C: The relative abundance of Lactobacillus, Bacilli, Lactobacillales, Lactobacillaceae, Streptococcus, Lachnospiraceae, Blautia, Pseudomonadaceae, and Pseudomonas among groups (control, model, oxymatrine). Class A: Control; Class B: Model; Class C: Oxymatrine; LDA: Linear discriminant analysis.

Citation: Xiong JF, He Y, Jiang N, Liu YH, Chen GF, Zhao CQ, Zhang SY, Wu YJ, Xu H. Modulation of the gut-liver axis by oxymatrine alleviates metabolic dysfunction-associated steatotic liver disease. World J Gastroenterol 2026; 32(16): 116187
URL: https://www.wjgnet.com/1007-9327/full/v32/i16/116187.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i16.116187

Xiong JF, He Y, Jiang N, Liu YH, Chen GF, Zhao CQ, Zhang SY, Wu YJ, Xu H. Modulation of the gut-liver axis by oxymatrine alleviates metabolic dysfunction-associated steatotic liver disease. World J Gastroenterol 2026; 32(16): 116187 [DOI: 10.3748/wjg.v32.i16.116187]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.